GW Henssler & Associates Ltd. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the second quarter, HoldingsChannel.com reports. The firm owned 119,457 shares of the company’s stock after purchasing an additional 1,276 shares during the period. Johnson & Johnson comprises 1.4% of GW Henssler & Associates Ltd.’s investment portfolio, making the stock its 23rd largest position. GW Henssler & Associates Ltd.’s holdings in Johnson & Johnson were worth $14,495,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of JNJ. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares during the period. Cornerstone Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock worth $20,537,000 after purchasing an additional 2,473,105 shares during the period. Bank of Montreal Can boosted its holdings in shares of Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock worth $838,515,000 after purchasing an additional 1,833,622 shares during the period. Summit Trail Advisors LLC boosted its holdings in shares of Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,752,841 shares during the period. Finally, Public Employees Retirement Association of Colorado boosted its holdings in shares of Johnson & Johnson by 212.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock worth $181,770,000 after purchasing an additional 1,019,002 shares during the period. Institutional investors own 66.06% of the company’s stock.
In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of the firm’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the completion of the transaction, the chief executive officer now owns 481,254 shares of the company’s stock, valued at $70,243,833.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Insiders have sold 351,748 shares of company stock valued at $51,092,647 in the last ninety days. Insiders own 0.22% of the company’s stock.
JNJ stock opened at $146.90 on Friday. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.75. The stock has a market capitalization of $391.30 billion, a P/E ratio of 18.35, a P/E/G ratio of 2.28 and a beta of 0.58. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. Johnson & Johnson’s revenue was up 3.6% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is 49.32%.
WARNING: “GW Henssler & Associates Ltd. Has $14.50 Million Stake in Johnson & Johnson (JNJ)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/12/01/gw-henssler-associates-ltd-has-14-50-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.